Lifecore Biomedical, Inc. cash flow to debt ratio of -0.14% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Lifecore Biomedical, Inc.'s free cash flow has increased -24.90% from $-18.14M last year to $-13.62M, signaling increasing performance

Lifecore Biomedical, Inc.'s debt to equity ratio is 7.23, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Lifecore Biomedical, Inc.'s debt has decreased relative to shareholder equity from 11.81 last year to 7.23 today, signaling strengthened financials

Lifecore Biomedical, Inc. has a net debt to EBITDA ratio of 15.18x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Interest expense is not separately reported in Lifecore Biomedical, Inc.'s latest filing, so interest coverage cannot be calculated.

Lifecore Biomedical, Inc.'s profit margin has increased (-16.05%) in the last year from -30.04% to -25.22%, signaling increasing performance

Lifecore Biomedical, Inc.'s short-term assets of $82.29M exceed its short-term liabilities of $23.57M

Lifecore Biomedical, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Lifecore Biomedical, Inc.'s return on equity of -176.12%, is lower than 15.00%, indicating bad performance

Lifecore Biomedical, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Lifecore Biomedical, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Lifecore Biomedical, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Lifecore Biomedical, Inc. has negative free cash flow, indicating cash burn

Lifecore Biomedical, Inc.'s yearly earnings has increased -20.47% since last year from $-38.72M to $-30.79M, signaling increasing performance

Lifecore Biomedical, Inc.'s yearly revenue has increased 0.47% since last year from $128.26M to $128.87M, signaling increasing performance

ROIC -0.04% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Lifecore Biomedical, Inc.'s 3-year revenue CAGR of 7.83% is positive, indicating growing revenue over the past 3 years

Lifecore Biomedical, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Lifecore Biomedical, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Lifecore Biomedical, Inc. has insufficient data to evaluate this check.

Lifecore Biomedical, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lifecore Biomedical, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Lifecore Biomedical, Inc. has an EV/EBITDA ratio of 36.16x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Lifecore Biomedical, Inc. is overvalued relative to its fair value price of -6.20 based on Earnings Fair Value model

Lifecore Biomedical, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lifecore Biomedical, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Lifecore Biomedical, Inc. has a price-to-sales ratio of 1.28x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue